Related Experiment Videos
Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma
C Kjellman1, S P Olofsson, O Hansson
1Department of Cell and Molecular Biology, Section of Tumor Immunology, University of Lund, Lund, Sweden.
Abstract:
Human gliomas express TGF-beta but, so far the expression of downstream mediators has been investigated in only a few cell lines. We have examined tissue specimens of 23 gliomas: 3 astrocytomas grade II (AST), 8 anaplastic astrocytomas grade III (AAST), and 12 glioblastoma multiforme grade IV (GBM). We analyzed the mRNA expression of TGF-beta1, TGF-beta2, TGF-beta3, the TGF-beta receptors type I (TbetaR-I) and type II (TbetaR-II), Smad2, Smad3, and Smad4. mRNA expression of IL-10 and CD95 (FAS/APO-1) were also studied. We detected increased mRNA levels of the 3 TGF-beta isoforms, correlating with the degree of malignancy. TGF-beta3 mRNA was increased, particularly in AST and AAST, while TGF-beta1 and TGF-beta2 mRNAs were strongly expressed in GBM. TGF-beta normally up-regulates the TGF-beta receptors, and TbetaR-I and TbetaR-II showed stronger expression in all gliomas when compared to normal tissues. However, the mRNA expression of Smad2, Smad3, and Smad4 was decreased in GBM. IL-10 mRNA expression was detected in glioma tissues but not in glioma cell lines. No marked increase in the expression of soluble CD95 splicing variants was found in the gliomas compared with normal tissue. However, total CD95 mRNA was elevated among GBM tissues.
Insights
Human gliomas show increased TGF-beta signaling with higher malignancy. While TGF-beta receptors are upregulated, key downstream mediators like Smad proteins decrease in aggressive glioblastoma, suggesting complex pathway dysregulation.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Research
Background:
- Human gliomas exhibit Transforming Growth Factor-beta (TGF-beta) expression.
- Downstream mediator expression in gliomas is not fully understood, particularly in tissue specimens.
Purpose of the Study:
- To analyze the mRNA expression of TGF-beta isoforms, their receptors, and downstream mediators (Smads) in various grades of human gliomas.
- To investigate the expression of IL-10 and CD95 in relation to glioma malignancy.
Main Methods:
- Analysis of mRNA expression using tissue specimens from 23 gliomas (3 astrocytomas grade II, 8 anaplastic astrocytomas grade III, 12 glioblastoma multiforme grade IV).
- Quantification of TGF-beta1, TGF-beta2, TGF-beta3, TbetaR-I, TbetaR-II, Smad2, Smad3, Smad4, IL-10, and CD95 mRNA levels.
Main Results:
- Increased mRNA levels of all three TGF-beta isoforms correlated with glioma malignancy.
- TGF-beta receptors (TbetaR-I, TbetaR-II) showed enhanced expression in gliomas compared to normal tissue.
- Smad2, Smad3, and Smad4 mRNA expression decreased in glioblastoma multiforme (GBM).
- IL-10 mRNA was detected in glioma tissues but not cell lines; total CD95 mRNA was elevated in GBM.
Conclusions:
- TGF-beta signaling pathway components are dysregulated in human gliomas, with isoform-specific and receptor expression increasing with malignancy.
- Decreased expression of Smad mediators in high-grade gliomas suggests a potential disruption in TGF-beta signal transduction.
- IL-10 and CD95 expression patterns may also play a role in glioma progression.